Join the Oncology Voice Network. Join for Free
How a Bold Yes Became a Scientific Breakthrough
City of Hope Academic Research

How a Bold Yes Became a Scientific Breakthrough


Share This Article



Summary

Dr. Linda Malkas shares the story behind AOH1996—how one bold “yes” led to a new cancer drug and a legacy built from love and science.

Welcome back to Season 2  On the Edge of Breakthrough: Voices of Cancer Research. In this powerful episode, Dr. Monty Pal welcomes Dr. Linda Malkas, Dean of Translational Sciences at City of Hope, for a conversation that spans childhood stargazing in Queens to leading one of the most ambitious cancer drug developments in recent history.

Dr. Malkas shares how a chance encounter with a grieving father sparked her quest to take on an “undruggable” target, resulting in AOH1996, a promising molecule designed to selectively attack cancer cells while sparing healthy ones. Named in memory of 8-year-old Ana Olivia Healy, the drug is now moving through clinical trials and showing potential to improve standard of care treatments across multiple cancers.

This episode dives into the science, the setbacks, and the synchronicity that fueled this journey, from organic chemistry and DNA fascination to late-night lab work, multidisciplinary collaboration, and the unique ecosystem at City of Hope that made it all possible.

It’s a remarkable story of science, heart, and the human drive to say “yes” to the impossible. Listen now.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Partner Avatar Monty Pal

What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.

Podcast
Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.
Partner Avatar Monty Pal

Reengineering CAR T for Solid Tumors: What Glioblastoma Has Taught Us with Christine Brown, Ph.D.

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN